Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases.

ABSTRACT:

Introduction

Establishing efficacy of and molecular pathways for statins has the potential to impact incidence of Alzheimer's and age-related neurodegenerative diseases (NDD).

Methods

This retrospective cohort study surveyed US-based Humana claims, which includes prescription and patient records from private-payer and Medicare insurance. Claims from 288,515 patients, aged 45 years and older, without prior history of NDD or neurological surgery, were surveyed for a diagnosis of NDD starting 1 year following statin exposure. Patients were required to be enrolled with claims data for at least 6 months prior to first statin prescription and at least 3 years thereafter. Computational system biology analysis was conducted to determine unique target engagement for each statin.

R

SUBMITTER: Torrandell-Haro G 

PROVIDER: S-EPMC7687291 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature